Does progression influence the quality of life? – Data from patients with advanced breast cancer from the MaLife-Project. 2. Oktober 2018 Marschner N., Söling, U., Scholz, H., Azeh, I., Chiabudini, M., Kruggel, L., Jänicke, M., 2018. Oncol Res Treat 41 (suppl.4) (V493) 1st-line therapy of patients with Waldenström Macroglobulinemia: Treatment reality and outcome data from the German prospective TLN Registry. Knauf, W., Slawik, H.R., Bückner, U., Houet, L., Wetzel, N., Jänicke, M., Marschner, N., 2018. Oncol Res Treat 41 (suppl 4)(P181), 47-48… Weiterlesen Carfilzomib in combination with lenalidomide and dexamethasone or carfilzomib in combination with dexamethasone alone in patients with multiple myeloma who have received at least one prior therapy: Interim results of the non-interventional CARO study. Knauf, W., Ammon, A., Merling, M., Hurtz, H.-J., Vannier, C., Schulz, H., Marschner, N., Riedt, T., Potthoff, K., 2018. Oncol Res Treat 41 (suppl 4)(P572). Weiterlesen